BIO:ON Insight #15 · Sep 8, 2026
A whole company on one platform — so what proves the platform?
Ionis wins FDA approval for an RNA drug in Alexander disease with no Big Pharma partner, autoimmune CAR-T trials stop after three patient deaths, and Lilly buys an antibody-degradation platform for up to $2.9B. Same word, "platform": three very different companies.
What I learned this week
If there's one line for this week, it's this: a platform is a promise, and every promise eventually sends an invoice. What struck me most is that Ionis waited more than 20 years to collect on its. Autoimmune CAR-T got its invoice in the heaviest possible way. Next time you see "innovative platform" in a job ad, check how much of the promise has been kept so far. See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- FDA Approvals
Ionis wins FDA approval for the first disease-modifying RNA therapy in Alexander disease
IonisUS FDA
- Clinical Trials
Patient deaths in autoimmune CAR-T trials; Novartis and BMS pause
NovartisBristol Myers Squibb
- Pipeline Analysis
Lilly to acquire Merida Biosciences for up to $2.9B
Eli LillyMerida Biosciences
AI summary
- 1Ionis won FDA approval for Zanvastro, the first disease-modifying RNA drug for Alexander disease.
- 2Novartis and BMS paused autoimmune CAR-T trials after three patient deaths.
- 3Lilly is acquiring Merida Biosciences, which degrades only harmful antibodies, for up to $2.9B.
Relevant rolesRegulatory affairsCMC & QABD
Summary and tags generated by AI from the issue text.
References
- 1.
- 2.Autoimmune cell therapy safety: Novartis and BMS halt trials after patient deaths (opens in a new tab)
PharmaVoice / MedPage Today, Sep 1, 2026
- 3.Eli Lilly to acquire Merida Biosciences for up to $2.9B (opens in a new tab)
Quartz / Becker's Hospital Review, Aug 31, 2026
Related insights
Other issues covering the same companies, drugs or topics